Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model. - Wikidata - awgldk - TriplyDB

Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model.

Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model.

http://www.wikidata.org/entity/Q37131840

about

Melatonin Protects Against Hypoxia/Reoxygenation-Induced Dysfunction of Human Umbilical Vein Endothelial Cells Through Inhibiting Reactive Oxygen Species Generation

P2860

Q57118599-82E01F72-2ABB-4D21-9A68-98A6182F248D

P2860

Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model.

http://www.wikidata.org/entity/Q37131840

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@en

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@nl

type

label

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@en

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@nl

prefLabel

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@en

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@nl

P1433

Q37131840-562320B6-419B-4B7F-914C-8DD2A38235AA

P1476

Q37131840-A63FA671-0403-4DBA-ABC4-B353C09F11DA

P2093

Q37131840-3AA52722-F94A-4AB4-8403-F7CE37023D7A

Q37131840-4874B9EB-D793-451A-9B02-F1FB206D3726

Q37131840-A4E7DCA9-2796-43E5-AA11-6A2CF1765290

Q37131840-DBD9D2D1-CB50-4E75-B20B-FEF05DB7D4EB

P2860

Q37131840-001285C4-F040-40D2-B21C-31AD57B89B52

Q37131840-05E97EE3-6683-40F4-ADDB-0BA57CF51C66

Q37131840-0E1492C7-AD59-4A49-BD13-E351AA01B980

Q37131840-1F387988-6BC2-4728-B01C-B7672C201B21

Q37131840-2F059AF7-96B6-490D-B67F-0D196598F9CD

Q37131840-357E51DB-7310-422C-AD8C-353C2637EC6F

Q37131840-78E3E7A4-BC4B-40FB-A12D-F38BA4654C65

Q37131840-7D9B2893-567F-4916-9913-AC60DF41B8D0

Q37131840-88D4CF66-290D-45FB-8F0B-6829A3FB52D6

Q37131840-9F062C85-C816-41F5-A735-69D77973842A

P304

Q37131840-7E0A4A18-AE36-416C-8B44-1CB45C98D5D2

P31

Q37131840-1195453E-046E-45BA-BCA8-0987482C4B8F

P356

Q37131840-311464FF-FFD8-431B-9C1F-7E348A1A73ED

P433

Q37131840-E226FC23-2D96-434B-AFDA-BDE1A1CD362B

P478

Q37131840-1C402EB3-E7CC-4391-B701-5AC6894ADE30

P50

Q37131840-50294FB6-CAE1-4EE9-8825-850096E70647

Q37131840-590C1DD4-09D5-4F54-8E6B-9EAE210D9E87

P577

Q37131840-8A273EB9-0BB7-41A0-BA72-BB5226753921

P698

Q37131840-B3BE6FC5-1DBA-4E26-9214-DEEDD0D7F69C

P921

Q37131840-FB94A431-26AB-4070-84CB-0573A7C023A5

P932

Q37131840-242AF1A1-5FDF-414C-A0B8-0133189E432F

P356

P1433

Acta Cardiologica Sinica

P1476

Optimal Duration of Coronary L ...... n Injury Study in a Rat Model.

@en

P2093

Kuo-Li Pan

http://www.w3.org/2001/XMLSchema#string

Shih-Tai Chang

http://www.w3.org/2001/XMLSchema#string

Teng-Yao Yang

http://www.w3.org/2001/XMLSchema#string

Wen-Jin Cherng

http://www.w3.org/2001/XMLSchema#string

P2860

Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AM

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.

Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

Recovery of the heart after normothermic ischemia. Part II: Myocardial function during postischemic reperfusion.

Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat.

Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow.

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.

The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study.

P304

491-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6515/ACS20150824B

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27471363

http://www.w3.org/2001/XMLSchema#string

P921

reperfusion injury

P932

4963426

http://www.w3.org/2001/XMLSchema#string